Development of new and more effective antipsychotics for Schizophrenia has been slow. Trends contributing to the slow pace of progress include increasing placebo response and declining treatment effect in clinical trials.

In this article, “The Impact of Aberrant Data Variability on Drug–Placebo Separation and Drug/Placebo Response in an Acute Schizophrenia Clinical Trial”, the authors explain how data analytics can be applied to clinical trials to predict robust placebo response and diminished drug-placebo separation.

Download the article to learn more and get recommendations for interventions that can help minimize risks to endpoint data quality.